GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ITOS stock, giving a Buy rating on November 12. Daina ...

Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Under his leadership, the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

GSK has shifted towards a global marketing ... While the new CEO has made some high-profile changes to the company’s management team, there have been some changes to the way the company ...

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...